Pharmacokinetics of meropenem in febrile neutropenic patients

被引:0
作者
A. Nyhlén
B. Ljungberg
I. Nilsson-Ehle
I. Thuresson
S. Glans
S. Rödjer
R. Lindblad
M. Polgary
B. Bäckström
L. Eliasson
S. Wennerholm
机构
[1] University Hospital of Lund,Department of Infectious Diseases
[2] University Hospital,Department of Internal Medicine
[3] East Hospital,Department of Internal Medicine
[4] University Hospital,Department of Internal Medicine
[5] University Hospital,Department of Infectious Diseases
来源
European Journal of Clinical Microbiology and Infectious Diseases | 1997年 / 16卷
关键词
Internal Medicine; Healthy Subject; Neutropenia; Minimum Inhibitory Concentration; Inhibitory Concentration;
D O I
暂无
中图分类号
学科分类号
摘要
To determine the impact of neutropenia on the pharmacokinetics of meropenem, 14 patients with fever and neutropenia were given 1 g of meropenem i.v. every 8 h as an infusion over 30 min. The volume of distribution (16.2 1/1.73 m2) and the nonrenal clearance [75 ml/(min x 1.73 m2)] in this group were significantly increased compared to healthy subjects studied previously with identical techniques. The kinetic study was repeated when the patients had a normal temperature and a raised neutrophil count; most kinetic variables did not differ from the findings on the first day of treatment. The pharmacokinetic profile of meropenem in febrile neutropenic patients differs from earlier findings in healthy subjects. Considering these data and known minimum inhibitory concentration values for common pathogens, meropenem administered every 6 to 8 h seems an appropriate regimen in patients with febrile neutropenia. The shorter time interval may be used for treatment ofPseudomonas infection.
引用
收藏
页码:797 / 802
页数:5
相关论文
共 82 条
[1]  
Cometta A(1996)Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer Antimicrobial Agents and Chemotherapy 40 1108-1115
[2]  
Calandra T(1995)Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients Journal of Antimicrobial Chemotherapy 36 185-200
[3]  
Gaya H(1988)Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acute ill males European Journal of Clinical Pharmacology 34 179-186
[4]  
Zinner SH(1992)Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men Antimicrobial Agents and Chemotherapy 36 1437-1440
[5]  
de Bock R(1989)Age dependence of renal function: clearance of iohexol and p-amino hippurate in healthy males Scandinavian Journal of Clinical Laboratory Investigation 49 641-646
[6]  
Del Favero A(1981)Reference values for Scandinavian Journal of Clinical Laboratory Investigation 41 611-616
[7]  
Bucaneve G(1984)Cr-EDTA as a measure of GFR Journal of Laboratory and Clinical Medicine 104 955-961
[8]  
Crokaert F(1991)Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate European Journal of Clinical Microbiology & Infectious Diseases 10 85-88
[9]  
Kern WV(1991)Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males Scandinavian Journal of Infectious Diseases Supplement 74 218-234
[10]  
Klastersky J(1988)Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values and bacterial eradication in patients with gram-negative pneumonia Journal of Infectious Diseases 158 831-847